Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non‐Hodgkin lymphoma
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Resistance to
Bruton tyrosine kinase
inhibition in
chronic lymphocytic leukaemia
and
non‐Hodgkin
lymphoma
Authors
Keywords
-
Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2022-08-27
DOI
10.1111/bjh.18418
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mechanisms of Resistance to Noncovalent Bruton’s Tyrosine Kinase Inhibitors
- (2022) Eric Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab
- (2022) John F. Seymour et al. BLOOD
- Long-term Outcomes for Ibrutinib-Rituximab and Chemoimmunotherapy in CLL: Updated Results of the E1912 Trial
- (2022) Tait D. Shanafelt et al. BLOOD
- A two‐part, single‐arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B‐cell malignancies
- (2022) Yuqin Song et al. BRITISH JOURNAL OF HAEMATOLOGY
- Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma
- (2022) Michael L. Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of B-cell receptor signaling disrupts cell adhesion in mantle cell lymphoma via RAC2
- (2021) Wenjun Wu et al. Blood Advances
- Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
- (2021) Anthony R Mato et al. LANCET
- Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication
- (2021) Pin Lu et al. Blood Cancer Journal
- First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia.
- (2021) John C. Byrd et al. JOURNAL OF CLINICAL ONCOLOGY
- Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway
- (2021) C. I. Edvard Smith et al. Frontiers in Immunology
- Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma
- (2021) Constantine S. Tam et al. Blood Advances
- Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL
- (2021) Wyndham H. Wilson et al. CANCER CELL
- Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma
- (2021) Preetesh Jain et al. JOURNAL OF CLINICAL ONCOLOGY
- Zanubrutinib Monotherapy for Relapsed or Refractory Non-Germinal Center Diffuse Large B-Cell Lymphoma
- (2021) Haiyan Yang et al. Blood Advances
- Resistance to Acalabrutinib in CLL Is Mediated Primarily By BTK Mutations
- (2020) Jennifer Woyach et al. BLOOD
- BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib
- (2020) Sasanka M. Handunnetti et al. BLOOD
- Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study
- (2020) Constantine S. Tam et al. BLOOD
- Regulation of B cell receptor-dependent NF-κB signaling by the tumor suppressor KLHL14
- (2020) Jaewoo Choi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications
- (2020) George W. Wright et al. CANCER CELL
- ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
- (2020) Paolo Ghia et al. JOURNAL OF CLINICAL ONCOLOGY
- Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial
- (2020) Jeff P Sharman et al. LANCET
- A RANDOMIZED PHASE 3 TRIAL OF ZANUBRUTINIB VERSUS IBRUTINIB IN SYMPTOMATIC WALDENSTRÖM MACROGLOBULINEMIA:THE ASPEN STUDY
- (2020) Constantine S. Tam et al. BLOOD
- Prognostic and Predictive Molecular Biomarkers in Chronic Lymphocytic Leukemia
- (2020) Jimmy Lee et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis
- (2020) Holly A. Hill et al. Blood Advances
- Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model
- (2020) Inhye E. Ahn et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting phosphatidylinositol 3 kinase-β and -δ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma
- (2020) Neeraj Jain et al. Blood Advances
- Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis
- (2020) Ariela Noy et al. Blood Advances
- Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial
- (2020) Steven Le Gouill et al. BLOOD
- Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma
- (2019) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma
- (2019) Peter Martin et al. BLOOD
- Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis
- (2019) Susan M. O'Brien et al. AMERICAN JOURNAL OF HEMATOLOGY
- Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma
- (2019) Liang Zhang et al. Science Translational Medicine
- Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell DLBCL
- (2019) Andre Goy et al. BLOOD
- Prevalence of BTK and PLCG2 mutations in a real‑life CLL cohort still on ibrutinib after three years: a FILO group study
- (2019) Anne Quinquenel et al. BLOOD
- Phase 1 study of selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
- (2019) Constantine Si Lun Tam et al. BLOOD
- A PHASE IIA STUDY EVALUATING THE SAFETY AND TOLERABILITY OF UMBRALISIB AND IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
- (2019) M. Lunning et al. HEMATOLOGICAL ONCOLOGY
- Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
- (2019) Tait D. Shanafelt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Final analysis from RESONATE: up to 6 years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
- (2019) Talha Munir et al. AMERICAN JOURNAL OF HEMATOLOGY
- Cutting Edge: ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor–BTK Signaling Pathway
- (2019) Qian Zhang et al. JOURNAL OF IMMUNOLOGY
- Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies
- (2019) Jennifer Woyach et al. BLOOD
- Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial
- (2019) Michael L. Wang et al. BLOOD
- Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
- (2019) Jan A. Burger et al. LEUKEMIA
- Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies
- (2019) Isha Kapoor et al. Cell Death & Disease
- Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience
- (2018) Susan O’Brien et al. BLOOD
- Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL)
- (2018) Preetesh Jain et al. BRITISH JOURNAL OF HAEMATOLOGY
- Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial
- (2018) Michael Wang et al. LANCET
- Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
- (2018) Bjoern Chapuy et al. NATURE MEDICINE
- Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
- (2018) Roland Schmitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
- (2018) Constantine S. Tam et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib
- (2018) Preetesh Jain et al. BRITISH JOURNAL OF HAEMATOLOGY
- LOXO-305, A Next Generation Reversible BTK Inhibitor, for Overcoming Acquired Resistance to Irreversible BTK Inhibitors
- (2018) Barbara Brandhuber et al. Clinical Lymphoma Myeloma & Leukemia
- Randomized trial of ibrutinib versus ibrutinib plus rituximab in patients with chronic lymphocytic leukemia
- (2018) Jan A. Burger et al. BLOOD
- TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics
- (2018) Elias Campo et al. HAEMATOLOGICA
- Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow-up from a pooled analysis
- (2018) Simon Rule et al. HAEMATOLOGICA
- Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
- (2018) Carol Moreno et al. LANCET ONCOLOGY
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
- (2018) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia
- (2017) Jennifer A. Woyach et al. JOURNAL OF CLINICAL ONCOLOGY
- Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial
- (2017) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma
- (2017) Xiaohong Zhao et al. Nature Communications
- Postibrutinib outcomes in patients with mantle cell lymphoma
- (2016) P. Martin et al. BLOOD
- Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience
- (2016) A. R. Mato et al. BLOOD
- Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study
- (2016) Martin Dreyling et al. LANCET
- Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial
- (2016) Michael L Wang et al. LANCET ONCOLOGY
- Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant
- (2016) A Hamasy et al. LEUKEMIA
- Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition
- (2016) Jan A. Burger et al. Nature Communications
- Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL
- (2016) Shruti Sharma et al. Oncotarget
- Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations
- (2016) Chenglin Wu et al. Oncotarget
- CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma
- (2016) Atish Mohanty et al. Oncotarget
- Hypermorphic mutation of phospholipase C, 2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation
- (2015) T.-M. Liu et al. BLOOD
- Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial
- (2015) K. Fischer et al. BLOOD
- Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
- (2015) P. Jain et al. BLOOD
- Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
- (2015) M. L. Wang et al. BLOOD
- Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma
- (2015) Shuang Q. Zhang et al. BRITISH JOURNAL OF HAEMATOLOGY
- Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo
- (2015) S. E. M. Herman et al. CLINICAL CANCER RESEARCH
- Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib - Findings from an Investigator-Initiated Phase II Study
- (2015) C. U. Niemann et al. CLINICAL CANCER RESEARCH
- Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial
- (2015) Mohammed Z H Farooqui et al. LANCET ONCOLOGY
- Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
- (2015) Wyndham H Wilson et al. NATURE MEDICINE
- Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
- (2015) Steven P. Treon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib
- (2015) Ailin Guo et al. Oncotarget
- Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
- (2015) Kami J. Maddocks et al. JAMA Oncology
- Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells
- (2014) Jiao Ma et al. BRITISH JOURNAL OF HAEMATOLOGY
- Functional characterization of BTK C481S mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors
- (2014) S Cheng et al. LEUKEMIA
- Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study
- (2014) S E M Herman et al. LEUKEMIA
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- (2014) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib Resistance in Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
- (2014) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
- (2013) J. A. Dubovsky et al. BLOOD
- BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity
- (2013) S Cheng et al. LEUKEMIA
- Pharmacological and genomic profiling identifies NF-κB–targeted treatment strategies for mantle cell lymphoma
- (2013) Rami Rahal et al. NATURE MEDICINE
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- (2013) Michael L. Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia
- (2012) M. F. M. de Rooij et al. BLOOD
- Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
- (2011) S. E. M. Herman et al. BLOOD
- The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
- (2011) S. Ponader et al. BLOOD
- Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling
- (2011) Chiara Pighi et al. CELLULAR ONCOLOGY
- Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era
- (2010) P. Perez-Galan et al. BLOOD
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
- (2010) R. Eric Davis et al. NATURE
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
- (2010) L. A. Honigberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma
- (2009) Mara Compagno et al. NATURE
- Stromal Gene Signatures in Large-B-Cell Lymphomas
- (2008) G. Lenz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways
- (2008) G. Lenz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma
- (2008) G. Lenz et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now